Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

INTERIM RESULTS HIGHLIGHTS

	Six months ended June 30,		Year-on-year
	2025	2024	change
	RMB'000	*RMB'000*	*(%)*
	(Unaudited)	(Unaudited)	
Revenue	**253,767**	197,457	28.5%
Gross profit	**154,954**	107,407	44.3%
Gross profit margin (%)	**61.1%**	54.4%	
Profit before tax	**115,677**	58,512	97.7%
Profit for the period	**101,999**	50,567	101.7%
Net profit margin (%)	**40.2%**	25.6%	

The board (the "**Board**") of directors (the "**Directors**") of Medtide Inc. (the "**Company**") is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (collectively, the "**Group**") for the six months ended June 30, 2025 (the "**Reporting Period**"). The contents of this interim results announcement have been prepared in accordance with applicable disclosure requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") in relation to preliminary announcement of interim results.

In this announcement, "we", "us", and "our" refer to the Company (as defined above) and where the context otherwise requires, the Group (as defined above).

Reference is made to the prospectus of the Company dated June 20, 2025 (the "**Prospectus**"). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

MANAGEMENT DISCUSSION AND ANALYSIS

In the first half of 2025, building upon the solid foundation established in 2024 and project pipelines, we sustained business growth. As an important player in the fast growing global peptide drug industry, we are committed to driving sustainable business and profit growth through world-class integrated CRDMO services for peptides and oligonucleotides, while continuing to empower global partners and support the broader development of Tides drugs development.

– We successfully finished Global Offering (as defined in the Prospectus) and achieved the important milestone to become a listed company in June 2025.

– Leveraging our established CRDMO capabilities and integrated platform facilities spanning from drug discovery to commercial manufacturing, we had established stable customer relationships and service footprint in over 50 countries. We offer customers full-cycle solutions of peptide synthesis, development and production, and assist them with regulatory submissions and approvals.

– In the current period of growing peptide industry, we captured the opportunities with our rapid expansion. And we keep expanding our customer coverage globally, and participate peptide drug pipelines from discovery stage, clinical stage and commercial stage as well. We are prepared and intend to further grow within the vast global Tides drug market, particularly in the GLP-1 peptide segment.

– In January 2025, we received ISO 22716:2007 Cosmetics Good Manufacturing Practices Certification. In March 2025, we obtained the marketing approval for Goserelin Acetate APIs in China. In addition, the utilization rates for our production lines stayed at a high level during the Reporting Period.

– To ensure we fulfill the growing global customer demand for Tides CRDMO services, we are actively expanding facilities and recruiting talents. As of June 30, 2025, our full-time employees reached 520, representing a 14.5% year-over-year increase from June 30, 2024.

Business Review

Key Operating Data

The following table sets forth certain of our key operating data for the periods indicated:

	Six months ended June 30,	
	2025	2024
Number of ongoing projects[(1)] at the beginning of the period	**1,549**	1,449
Number of new projects[(1)] secured during the period	**4,674**	4,353
Number of projects closed[(2)] at the end of the period	**4,760**	4,424
Number of ongoing projects[(1)] at the end of the period	**1,463**	1,378

Notes:

(1) The numbers of projects includes both Peptide and Oligonucleotide projects.

(2) For CRO projects, a project is considered closed once the products have been delivered. For CDMO projects, a project is considered closed once the project is completed or discontinued.

	Six months ended June 30,	
Number of on-going projects at the end of the period	**2025**	2024
CRO	**1,125**	1,046
CDMO (CMC development stage)	**325**	319
CDMO (Commercial manufacturing stage)	**13**	13
Total	**1,463**	1,378

Overview

TIDES CRDMO overall performance

– Guided by "going with the compound" strategy and making full use of our integrated CRDMO platform advantages, our TIDES CRDMO business keeps growing. We achieved the following performance indicators.

  - Our revenue increased by 28.5% from RMB197.5 million in the six months ended June 30, 2024 to RMB253.8 million in the six months ended June 30, 2025.

  - Our gross profit increased by 44.3% from RMB107.4 million in the six months ended June 30, 2024 to RMB155.0 million in the six months ended June 30, 2025.

  - Our net profit increased by 101.7% from RMB50.6 million in the six months ended June 30, 2024 to RMB102.0 million in the six months ended June 30, 2025.

  - Our adjusted net profit (non-IFRS measure)[(1)] increased by 14.9% from RMB90.6 million in the six months ended June 30, 2024 to RMB104.1 million in the six months ended June 30, 2025.

  - Our ongoing CDMO project number increased from 332 as of June 30, 2024 to 338 as of June 30, 2025.

Note:

(1) We define adjusted net profit (non-IFRS measure) for the period, as profit for the period adjusted by adding back (i) fair value gains/(losses) on financial liabilities at fair value through profit or loss ("**FVTPL**") comprises fair value gains/(losses) on redemption liabilities, of which the redemption liabilities will convert to equity upon the Listing, (ii) share-based payment compensation, which are non-cash in nature, and (iii) listing expenses.

Our Services

We are one of the most comprehensive peptide focused CRDMO globally, offering full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. We mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Our services primarily focus on providing customers with APIs rather than drug products. Our customers use the APIs with excipients to create the final dosage forms of drug products, determine the appropriate dosage form, route of administration, and formulation, and then use the final drug products for their clinical trials or commercial sales. We have established stable customer relationships and service footprint in over 50 countries, including major markets such as China, the United States, Japan, Europe, South Korea, and Australia. We provide our customers with peptide drug development, production, and CMC filing support services that meet regulatory requirements in major markets worldwide.

The following chart sets forth details of our end-to-end services across the peptide drug lifecycle.



Notes:

(1) Scale up refers to the process of transforming a lab-scale product into a commercially viable product by developing a reliable manufacturing technique. This technique is designed to accommodate various output volumes, which are typically larger than lab-scale.

(2) Our services primarily focus on providing customers with APIs rather than drug products. We do not produce drug products that are directly used in clinical trials or commercially.

Leveraging our deep and long-standing experience in the global peptide industry and broad customer base, we are also well-positioned to ride the industry tailwind of oligonucleotide drugs. We strategically provide oligonucleotide CDMO service to our customers, covering preclinical research, clinical development and commercial-stage production.

Technology Platforms

As of June 30, 2025, our R&D department had 61 employees, nearly 40% of whom held a master's degree or above. Our R&D activities focus to strengthen our technologies to maintain our competitive advantages. Our team is highly adept in advanced synthesis methods for complex and long peptide chains, such as solid-phase synthesis, liquid-phase synthesis, hybrid solid-liquid-phase synthesis, and fragment condensation synthesis. We have also mastered the technologies of super-long peptide chain synthesis, cyclopeptide synthesis, difficult sequence peptide synthesis, diversified peptide modification and multiple disulfide bridge peptides.

Our proprietary technological platforms include:

- ***OmniPeptSynth™***: Leveraging it, we excel in efficiently and precisely synthesizing a wide range of peptides, from complex to challenging sequences, and even super-long peptides.

- ***PeptiConjuX™ and PeptiNuclide LinkTech™***: Our PeptiConjuX™ and PeptiNuclide LinkTech™ platforms provide customized synthesis, conjugation, development and production of conjugate peptide API products. Our PeptiConjuX™ platform integrates advanced peptide modification techniques, such as proprietary on-resin cyclization, N-methylation, phosphorylation, glycosylation, and diverse forms of PEGylation. The PeptiNuclide LinkTech™ platform stands as our premier in-house solution for peptide-nuclear drug conjugation.

- ***GreenSynth Innovations™***: GreenSynth Innovations™ stands as a cornerstone of our advantage in the realm of green chemistry. This platform is dedicated to reshaping production processes, minimizing the use and generation of harmful substances and driving down production costs, all in line with our commitment to sustainability.

- ***Impurity Screening™***: This platform boasts mature and unique processes for analyzing and preparing peptide impurities, alongside dedicated technical support.

In addition to the above, we have GreenPepisolate™ and DisulfideDetect™. GreenPepisolate™ ensures high-efficiency peptide separation while maintaining superior product purity and yield. DisulfideDetect™ is an advanced technology for analyzing the localization of disulfide bonds.

Quality Management

We believe that an effective quality management system is critical to ensuring the quality of our services and maintaining our reputation and success. We maintain a very high standard, quality assurance and quality control department, which is responsible for supervising the implementation of the quality standards. As of June 30, 2025, our quality assurance and quality control department consisted of a total of 100 staff members. We had passed every quality inspections by customers over the past five years. We passed GMP inspections from various regulatory authorities and quality organizations, including five FDA on-site GMP inspections, and three on-site and remote GMP inspections from other overseas regulatory authorities including MFDS, EMA and TGA; Over the past five years, we had also passed nine on-site GMP or registration inspection from the NMPA. We had also obtained the ISO9001 and ISO13485 certifications.

During the Reporting Period, we accepted and passed regulatory and customer audit for 17 times, including domestic and overseas customers.

Manufacturing Capacity

With more than two decades of continuous development and operation experience accumulation, we have extensive peptide API production capacity equipped with a comprehensive digitized system of project research and innovation. Our cGMP-compliant production facility of Qiantang site in Hangzhou has a total gross floor area of over 20,000 square meters, with an annual API production capacity of over 500 kilograms and per-batch production capability of over 30 kilograms, capable of handling multiple 100 kilogram level peptide orders. The Qiantang Site also has the capacity to manufacture 1-17kg of oligonucleotides per year. Our international operations are based in Rocklin, California, the United States.

As of June 30, 2025, we have started new expansion in Rocklin Site (California) and in Qiantang Site, including 3,000 liter SPPS reactor among other new production lines installation.

Business Development

Operating globally, we have sales offices with dedicated sales and marketing teams in China, United States and Europe. While our existing customer base is strong in North America and China, we are strategically expanding our reach into European and Asian markets. We are also enhancing our business development resources to penetrate oligonucleotide drugs market.

During the Reporting Period, we actively participated in many industry conferences, trade exhibitions, and scientific meetings, such as DCAT 2025, Swiss Biotech Day, RNA Leaders Europe Congress, TIDES Asia 2025, TIDES USA, CPHI China 2025, and the International Oligonucleotides and Peptides Conference (IOPC). As a result, we have been able to continuously expand our customer base and increase the number of clients served annually. We plan to engage in more of these industry events and specific client meetings to enhance brand awareness while executing our broader global marketing initiatives. Since the Company's founding, our senior executives, including the CEO and CBO, have been continuously involved in sales management and marketing activities, maintaining direct communication with key clients.

Outlook

In the first half of 2025, the GLP-1 receptor agonist market, driven by semaglutide, tirzepatide, liraglutide, dulaglutide, and other key therapeutics, exhibited exceptional sales growth, reinforcing their pivotal role in addressing diabetes and obesity. Novo Nordisk's semaglutide products (Ozempic, Rybelsus, and Wegovy) achieved combined sales of DKK112.756 billion (US$16.683 billion), decisively outpacing Merck's Keytruda, which generated US$15.2 billion during the same period, thereby becoming the world's highest-selling pharmaceutical product by revenue in the first half of 2025. Meanwhile, tirzepatide demonstrated remarkable growth momentum across its dual indications, with combined revenue reaching US$14.73 billion. The robust performance reflects the enormous unmet medical need in diabetes and obesity management. According to Frost & Sullivan, the global peptide drug market is projected to grow from US$89.5 billion in 2023 to US $261.2 billion by 2032, with a CAGR of 12.6%. The GLP-1 drug market is expected to outpace this growth, expanding from US$38.9 billion in 2023 to US$129.9 billion by 2032 at a CAGR of 14.3%, underscoring the increasing demand and therapeutic impact of these innovative treatments.

We have built an extensive project pipeline, and strategically focused on the pipelines in the field of GLP-1. As of June 30, 2025, our project pipeline included 338 ongoing CDMO projects, including nine NCE GLP-1 molecule development projects with seven customers in developing oral and/or injectable GLP-1 molecule products.

Looking forward, we plan to leverage our solid foundation and align with market trends to seize opportunities and meet customer demands through the implementation of the following strategies, further expanding our competitive advantages in the industry.

– Implement our capacity expansion plan in the United States and China to meet customers' increasing demand and capture the rapid growth of the peptide CRDMO market.

  United States. We plan to start equipment installation of our Rocklin Site in the second half of 2025 to set up annual production capacity up to 300kg in US. The Rocklin Site will focus on GMP-compliant production of peptide APIs with designed single batch capacities ranging from grams to multi kilograms. The establishment of a production base in Rocklin will fulfill most of our customers' demand for US local production and delivery.

  China. We plan to further enhance the utilization of our existing production facility in Qiantang, Hangzhou. We have started new expansion including 3,000 liter SPPS reactor among other new production lines installation as of June 30, 2025. We expect to complete the expansion by the end of 2025, achieving an additional annual productivity of 500kg. Once the expansion completed, this will position Medtide group API production capacity to well over 1,000kg annually. This project aims to optimize the use of existing resources, enhance facility efficiency, and strengthen our production capabilities.

  Moreover, in addition to Qiantang Site and Rocklin Site, we intend to either construct or acquire new production facilities in the coming years. This is to bolster our annual API manufacturing to additional several metric tons, with batch capacity up to hundred kilograms. This expansion plan is in response to growing existing and potential customer demand for GLP-1 products, which are approaching advanced stages of clinical and commercial production.

– With our comprehensive technologies, production capabilities and globally compliance quality system on peptide and oligonucleotide, we will further implement "going with the compound" strategy to enhance our competitive advantages in the Tides industry. We prepare manufacturing capabilities and capacity according to pipelines' development plan and match production arrangement in addition to the need years forward. Some of our current projects are expected to enter into commercial production stage over the next three to five years, particularly GLP-1 pipelines. Meanwhile, with our additional capacity available, we seek for more advanced stage pipeline opportunities.

– We plan to focus our R&D efforts on developing cutting-edge technologies and continuous developing of selected generic products. We plan to conduct further CMC research on new TIDES related drugs, including GLP-1, PDC, RDC and POC drugs. We also plan to continuously enhance the automated production process which is expected to reduce quality risk, increase production efficiency, and improve our competitiveness. Meanwhile, we are continuously developing high-value generic products and actively preparing for their DMF submissions, in order to build a robust product pipeline for the future business expansion.

FINANCIAL REVIEW

Revenue

Revenue was RMB253.8 million for the six months ended June 30, 2025, representing a 28.5% increase from RMB197.5 million for the six months ended June 30, 2024, which was primarily due to the increase in revenue from FFS and FTE business driven by our customers' growing demand for our services.

The following table breaks down our revenue by fee model for the periods presented:

	Six months ended June 30,		Year-on-year
	2025	2024	change
	RMB'000	*RMB'000*	*(%)*
	(Unaudited)	(Unaudited)	
Revenue:			
FFS	**232,924**	192,944	20.7%
FTE	**20,843**	4,296	385.2%
Others	**–**	217	N/A
Total:	**253,767**	197,457	28.5%

The revenue from FFS was RMB232.9 million for the six months ended June 30, 2025, representing a 20.7% increase from RMB192.9 million for the six months ended June 30, 2024, which was mainly attributable to the increase in revenue from CDMO business, particularly from customers with advanced clinical stage or commercial projects.

The following table breaks down our revenue by services offering for the periods presented:

	Six months ended June 30,		Year-on-year
	2025	2024	change
	RMB'000	*RMB'000*	*(%)*
	(Unaudited)	(Unaudited)	
Revenue:			
CRO service	**55,570**	47,632	16.7%
CDMO service	**198,197**	149,608	32.5%
Others	**–**	217	N/A
Total:	**253,767**	197,457	28.5%

The revenue from CRO was RMB55.6 million for the six months ended June 30, 2025, representing a 16.7% increase from RMB47.6 million for the six months ended June 30, 2024, which was mainly attributable to the increase of FTE services demand from customers in the U.S..

The revenue from CDMO was RMB198.2 million for the six months ended June 30, 2025, representing a 32.5% increase from RMB149.6 million for the six months ended June 30, 2024, which was mainly attributable to the increase in revenue from customers with advanced clinical stage or commercial projects, driven by their respective drug development progress and increased demand for our services.

Cost of sales

Cost of sales was RMB98.8 million for the six months ended June 30, 2025, representing a 9.7% increase from RMB90.1 million for the six months ended June 30, 2024, due to the increase of production. Our cost of sales consists of material costs, staff compensation, utilities and other overhead, depreciation and amortization, share-based payment compensation, and others. The following table sets forth a breakdown of its cost of sales by nature in absolute amount for the periods indicated.

	Six months ended June 30,		Year-on-year
	2025	2024	change
	RMB'000	*RMB'000*	*(%)*
	(Unaudited)	(Unaudited)	
Cost of sales:			
Material costs	**36,322**	28,290	28.4%
Staff compensation	**29,987**	31,672	-5.3%
Utilities and other overhead	**12,218**	13,460	-9.2%
Depreciation and amortization	**8,995**	9,646	-6.7%
Share-based payment compensation	**951**	940	1.2%
Others	**10,340**	6,042	71.1%
Total:	**98,813**	90,050	9.7%

Gross profit and gross profit margin

As a result of the foregoing, gross profit was RMB155.0 million for the six months ended June 30, 2025, representing a 44.3% increase from RMB107.4 million for the six months ended June 30, 2024.

Gross profit margin was 61.1% for the six months ended June 30, 2025, representing an increase of 6.7 percentage points from 54.4% for the six months ended June 30, 2024. The increase in the gross profit margin was primarily due to the slower increase of cost of sales than that of revenue driven by lower staff compensation, utilities and other overhead.

Other income and gains

Our other income and gains decreased by 60.4% from RMB42.9 million in the six months ended June 30, 2024 to RMB17.0 million in the six months ended June 30, 2025. As we fulfilled all the conditions attaching to the Bond-related Grant (as defined in the Prospectus) in June 2024, the remaining Bond-related Grant is recognized as other income in 2024 and is one-off in nature.

Selling and marketing expenses

Selling and marketing expenses were RMB18.6 million for the six months ended June 30, 2025, representing a 7.5% increase from RMB17.3 million for the six months ended June 30, 2024. The increase was primarily due to increase of activities and events with customers align with sales revenue growth.

Administrative expenses

Administrative expenses were RMB40.5 million for the six months ended June 30, 2025, representing a 5.7% increase from RMB38.3 million for the six months ended June 30, 2024, primarily attributable to increase of listing expense.

Research and development expenses

Research and development expenses were RMB12.7 million for the six months ended June 30, 2025, representing a 2.3% decrease from RMB13.0 million for the six months ended June 30, 2024. The decrease was primarily attributable to the decrease of material cost.

Income tax expense

Income tax expense was RMB13.7 million for the six months ended June 30, 2025 compared to approximately RMB7.9 million for the six months ended June 30, 2024. Income tax expense for the six months ended June 30, 2025 was composed of current and deferred tax.

Fair value gains/(losses) on financial liabilities at FVTPL

Fair value gain on financial liabilities at FVTPL was RMB18.5 million for the six months ended June 30, 2025, compared with the fair value loss on financial liabilities at FVTPL of RMB21.7 million for the six months ended June 30, 2024. The change in the fair value on financial liabilities at FVTPL was primarily attributable to changes in the valuation of our Company.

Profit for the period

As a result of the foregoing, the profit for the six months ended June 30, 2025 reached RMB102.0 million, compared with a profit of RMB50.6 million for the six months ended June 30, 2024. The increase was primarily due to the increase of gross profit and fair value gains on financial liabilities at FVTPL.

Non-IFRS Measures

To supplement our consolidated financial statements, which are presented in accordance with International Financial Reporting Standards (the "**IFRSs**"), we also use adjusted net profit as an additional financial measure, which is not required by, or presented in accordance with, IFRSs.

We believe adjusted net profit provides useful information to investors and others in understanding and evaluating our consolidated results of operations in the same manner as they help our management. However, our presentation of adjusted net profit may not be comparable to similarly titled measures presented by other companies. The use of adjusted net profit has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for an analysis of, our results of operations or financial condition as reported under IFRSs.

We define adjusted net profit (non-IFRS measure) for the period, as profit for the period adjusted by adding back (i) fair value gains/(losses) on financial liabilities at FVTPL comprises fair value gains/(losses) on redemption liabilities, of which the redemption liabilities will convert to equity upon the Listing, (ii) share-based payment compensation, which are non-cash in nature, and (iii) listing expenses.

The following table reconciles our adjusted net profit for the periods presented to the most directly comparable financial measure calculated and presented in accordance with IFRSs, which is profit for the six months ended June 30, 2025 and 2024:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Reconciliation of profit to adjusted net profit (Non-IFRS measure):		
Profit for the period	**101,999**	50,567
Add:		
Fair value (gains)/losses on financial liabilities at FVTPL	**(18,463)**	21,683
Share-based payment compensation	**2,311**	2,132
Listing expenses	**18,211**	16,183
Adjusted net profit for the period (Non-IFRS measure)	**104,058**	90,565

Liquidity and capital resource

The Board and the Audit Committee constantly monitor current and expected liquidity requirements to ensure that the Company maintains sufficient reserves of cash to meet its liquidity requirements in the short and long term.

For the six months ended June 30, 2025, we funded our cash requirements primarily from business operations, capital contribution from shareholders and issuance of equity shares as major sources of liquidity. With respect to cash management, our objective is to optimize liquidity to secure a stable return for shareholders in a risk-averse manner. Specifically, we have policies in place to monitor and manage the settlement of trade receivables. When determining the credit term of a customer, we consider a number of factors, including length of past cooperation and its past payment timeliness. To monitor the settlement of our trade receivables and avoid credit losses, we conduct annual review of each customer's financial performance, which is primarily based on the amount and aging of the trade receivables due from such customer in the respective period.

We had cash and cash equivalents of RMB998.4 million as of June 30, 2025, as compared to RMB387.2 million as of December 31, 2024, primarily due to cash generated from operation and proceeds from the Global Offering. Most of the cash and cash equivalents of the Group were denominated in Renminbi. Most of the time deposits of the Group were denominated in U.S. dollars.

Significant investments

We did not make or hold any significant investments (including any investment in an investee company with a value of 5% or more of the Group's total assets as of June 30, 2025) during the six months ended June 30, 2025.

Material acquisitions and/or disposals of subsidiaries, associates and joint ventures

We did not have any material acquisitions and/or disposals of subsidiaries and affiliated companies during the six months ended June 30, 2025.

Future plans for material investments and capital assets

As of June 30, 2025, save for "Future Plans and Use of Proceeds" disclosed in the Prospectus and as disclosed in this announcement, the Group did not have any future plan for material investments or capital assets.

Employee and remuneration

As of June 30, 2025, the number of our full-time employees amounted to 520, as compared to 454 as of June 30, 2024. The total employee benefit expenses for the six months ended June 30, 2025, including share-based payment expenses, were RMB71.1 million, as compared to RMB64.4 million for the six months ended June 30, 2024.

Bank borrowings and gearing ratio

As of June 30, 2025, our outstanding borrowings amounted to RMB50.0 million.

As of June 30, 2025, the Group's gearing ratio (i.e. total liabilities divided by total assets) was 17.1% (as of December 31, 2024: 72.8%), which was mainly due to the changed balance of redemption liabilities on equity shares and the proceeds from Global Offering (as defined in the Prospectus).

Contingent liabilities

As of June 30, 2025, we did not have any material contingent liabilities or guarantees.

Charges on assets

As of June 30, 2025, we did not pledge or charge any other assets except for the restricted cash pledged for foreign exchange trading and other operating activities.

Foreign exchange risk

Our foreign currency transactions, including sales, expose us to foreign currency risk. Certain of our bank balances and cash, trade receivables and trade payables are denominated in currencies other than the functional currency of the relevant group entities and expose us to such foreign currency risk (mainly related to US dollar, Hong Kong dollar, and European dollar). For the six months ended June 30, 2025, no financial instruments were used for hedging purposes, and the Group did not commit to any financial instruments to hedge its exposure to exchange rate risk, as the expected exchange rate risk is not significant.

The Directors and senior management will continue to monitor the foreign exchange exposure and will consider applicable derivatives when necessary.

During the six months ended June 30, 2025, exchange gains and losses from those foreign currency transactions denominated in a currency other than the functional currency were insignificant.

INTERIM FINANCIAL INFORMATION

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS
For the six months ended June 30, 2025

	Notes	**Six months ended June 30,**	
		2025	2024
		RMB'000	*RMB'000*
		(unaudited)	(unaudited)
REVENUE	*5*	**253,767**	197,457
Cost of sales		**(98,813)**	(90,050)
Gross profit		**154,954**	107,407
Other income and gains	*6*	**16,989**	42,857
Selling and marketing expenses		**(18,641)**	(17,267)
Administrative expenses		**(40,533)**	(38,304)
Research and development expenses		**(12,650)**	(12,998)
Impairment losses on financial assets, net		**(678)**	(839)
Other expenses		**(1,706)**	(151)
Finance costs		**(521)**	(510)
Profit before fair value gains/(losses) on financial liabilities at fair value through profit or loss		**97,214**	80,195
Fair value gains/(losses) on financial liabilities at fair value through profit or loss		**18,463**	(21,683)
PROFIT BEFORE TAX		**115,677**	58,512
Income tax expense	*7*	**(13,678)**	(7,945)
PROFIT FOR THE PERIOD		**101,999**	50,567
Attributable to:			
Owners of the parent		**101,999**	50,567
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic (RMB)	*9*	**0.82**	0.40
Diluted (RMB)	*9*	**0.82**	0.30

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the six months ended June 30, 2025

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
PROFIT FOR THE PERIOD	**101,999**	50,567
OTHER COMPREHENSIVE INCOME		
Items that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**(487)**	400
OTHER COMPREHENSIVE INCOME FOR THE PERIOD	**(487)**	400
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**101,512**	50,967
Attributable to:		
Owners of the parent	**101,512**	50,967

INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
As of June 30, 2025

	Notes	**As at June 30, 2025** ***RMB'000*** **(unaudited)**	As at December 31, 2024 *RMB'000* (audited)
NON-CURRENT ASSETS			
Property and equipment		**299,891**	300,484
Goodwill		**95,406**	95,406
Other intangible assets		**33,339**	36,016
Right-of-use assets		**37,327**	38,082
Financial assets at fair value through profit or loss		**1,805**	1,634
Prepayments, other receivables and other assets		**19,692**	7,183
Deferred tax assets		**26**	23
Total non-current assets		**487,486**	478,828
CURRENT ASSETS			
Inventories		**94,448**	84,777
Trade and notes receivables	*10*	**32,851**	57,720
Prepayments, other receivables and other assets		**8,513**	16,098
Restricted cash		**440**	439
Time deposits		**144,614**	143,032
Prepaid income tax		**4,732**	4,551
Cash and cash equivalents		**998,403**	387,183
Total current assets		**1,284,001**	693,800
CURRENT LIABILITIES			
Trade payables	*11*	**28,992**	23,469
Other payables and accruals		**52,126**	53,460
Interest-bearing bank borrowings		**50,000**	40,000
Contract liabilities		**126,286**	37,444
Lease liabilities		**398**	379
Amounts due to a related party		**–**	1,811
Deferred government grants		**6,412**	6,438
Income tax payable		**1,135**	9,042
Total current liabilities		**265,349**	172,043
NET CURRENT ASSETS		**1,018,652**	521,757
TOTAL ASSETS LESS CURRENT LIABILITIES		**1,506,138**	1,000,585

	Notes	**As at June 30, 2025** ***RMB'000*** **(unaudited)**	As at December 31, 2024 *RMB'000* (audited)
NON-CURRENT LIABILITIES			
Redemption liabilities on equity shares		**–**	639,805
Deferred government grants		**25,987**	29,072
Lease liabilities		**557**	764
Deferred tax liabilities		**10,691**	12,194
Total non-current liabilities		**37,235**	681,835
Net Assets		**1,468,903**	318,750
EQUITY			
Equity attributable to owners of the parent			
Share capital	*12*	**141,800**	125,000
Reserves		**1,327,103**	193,750
Total equity		**1,468,903**	318,750

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
June 30, 2025

1. CORPORATE INFORMATION

Medtide Inc. (the "Company") was established in the People's Republic of China ("PRC") on June 11, 2020, as a limited liability company. On February 10, 2023, the Company was converted into a joint stock company with limited liability under the Company Law of the PRC. The registered office of the Company is located at Room 501-11, Building 6, Yinhai Kechuang Center, Xiasha Street, Qiantang District, Hangzhou City, Zhejiang Province, PRC.

During the reporting period, the principal activity of the Company and its subsidiaries (together, the "Group") was to provide prominent contract research and development manufacturing organization ("CRDMO") services that specializes in synthetic peptide production.

2. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended June 30, 2025 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's financial information as set out in the accountants' report (the "Accountants' Report") included in Appendix I to the Company's prospectus dated June 20, 2025 in connection with the IPO of the Company's shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

This interim condensed consolidated financial information is presented in Renminbi ("RMB") and all values are rounded to the nearest thousand except when otherwise indicated.

3. CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2024, except for the adoption of the following amended IFRS Accounting Standard for the first time for the current period's financial information.

Amendments to IAS 21	*Lack of Exchangeability*

The nature and impact of the amended IFRS Accounting Standard are described below:

Amendments to IAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

4. SEGMENT INFORMATION

For the purpose of resource allocation and performance assessment, the Group's chief executive officer, being the chief operating decision maker, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment and no further analysis of this single segment is presented.

Geographical information

(a) Revenue from external customers

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Mainland China	**38,903**	56,624
United States of America ("USA")	**147,675**	121,990
Japan	**10,457**	2,573
Europe	**37,945**	5,551
Others	**18,787**	10,719
Total	**253,767**	197,457

The revenue information above is based on the locations of the contract entities of our customers.

(b) Non-current assets

	As at	As at
	June 30,	December 31,
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(audited)
Mainland China	**422,311**	418,599
Overseas	**63,099**	58,326
Total	**485,410**	476,925

The non-current asset information above is based on the locations of the assets and excludes financial instruments and deferred tax assets.

Information about major customers

Revenue from two customers, including sales to a group of entities which are known to be under common control with those customers, which accounted for 10% or more of the Group's revenue during the reporting period, is set out below:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Customer A	**99,352**	66,531
Customer B	**30,468**	1,162

5. REVENUE

An analysis of revenue is as follows:

Revenue from contracts with customers

Disaggregated revenue information

Types of goods and services	**Six months ended June 30,**	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
CRDMO services	**253,767**	197,240
Others	**–**	217
Total	**253,767**	197,457

Types of fee models	**Six months ended June 30,**	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Fee-for-service ("FFS")	**232,924**	192,944
Full-time-equivalent ("FTE")	**20,843**	4,296
Others	**–**	217
Total	**253,767**	197,457

Timing of revenue recognition	**Six months ended June 30,**	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Services and goods transferred at a point of time	**232,924**	192,944
Services transferred over time	**20,843**	4,513
Total	**253,767**	197,457

6. OTHER INCOME AND GAINS

An analysis of other income and gains is as follows:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Other income		
Government grants		
– income*	**4,940**	29,682
– assets**	**3,111**	–
Bank interest income	**8,609**	6,702
Total other income	**16,660**	36,384
Gains		
Foreign exchange differences, net	**–**	3,678
Fair value gains on financial assets at FVTPL	**170**	2,701
Others	**159**	94
Total gains	**329**	6,473
Other income and gains	**16,989**	42,857

* This represents government grants related to income that is received as compensation for expenses or for the purpose of giving immediate financial support to the Group. There are no unfulfilled conditions or contingencies relating to these grants.

** The Group had complied with all conditions attaching to the government grants related to assets which were recognized in profit or loss over the useful lives of the relevant assets.

7. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and/or operate.

Mainland China

Under the Law of the PRC on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the EIT rate for the Company and PRC subsidiaries was 25% during the reporting period.

Chinese Peptide Company was accredited as a "High and New Technology Enterprise" in 2021 and was entitled to a preferential corporate income tax rate of 15% from 2021 to 2023. This qualification is subject to review by the relevant tax authority in the PRC every three years. Chinese Peptide renewed its "High and New Technology Enterprise" qualification in 2023 and is entitled to the preferential tax rate of 15% from 2024 to 2026.

Hong Kong

The first Hong Kong dollars ("HK$") 2,000,000 of assessable profits of the subsidiary are taxed at 8.25% and the remaining assessable profits are taxed at 16.5%. No provision for Hong Kong income tax has been provided as the Group's Hong Kong entity had no estimated assessable profits during the reporting period.

USA

The Company's subsidiaries incorporated and operated in the USA were subject to the federal corporate income tax rate of 21% during the reporting period. These subsidiaries were also subject to the state income tax in California at a rate of 8.84% during the reporting period.

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Current – Mainland China	**14,679**	6,867
Current – USA	**505**	500
Deferred	**(1,506)**	578
Total	**13,678**	7,945

8. DIVIDEND

No dividend was declared or paid by the Company during the six months ended June 30, 2025 and 2024.

9. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit for the period attributable to ordinary equity holders of the parent and the weighted average number of shares outstanding during the six months ended June 30, 2025 and 2024.

The calculation of the diluted earnings per share amount for the six months ended June 30, 2024 is based on the profit for the period attributable to ordinary equity holders of the parent, adjusted to reflect fair value gains on convertible bonds. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares outstanding during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed conversion of all dilutive potential ordinary shares into ordinary shares.

The calculations of basic and diluted earnings per share are based on:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	**101,999**	50,567
Add: Fair value gain on convertible bonds	**–**	(10,781)
Profit attributable to ordinary equity holders of the parent before fair value gain on convertible bonds	**101,999**	39,786

	Number of shares ('000) Six months ended June 30,	
	2025	2024
	(unaudited)	(unaudited)
Ordinary shares		
Weighted average number of ordinary shares outstanding during the period used in the basic earnings per share calculation	**125,000**	125,000
Effect of dilution – weighted average number of ordinary shares:		
Convertible bonds	**–**	6,849
Total	**125,000**	131,849

10. TRADE AND NOTES RECEIVABLES

An aging analysis of the trade receivables as at the end of the reporting periods based on the invoice date and net of allowance for expected credit losses, is as follows:

	As at June 30, 2025	As at December 31, 2024
	RMB'000	*RMB'000*
	(unaudited)	(audited)
Within 1 year	**32,498**	57,460
1 to 2 years	**350**	240
2 to 3 years	**3**	20
Total	**32,851**	57,720

11. TRADE PAYABLES

An aging analysis of the trade payables as at the end of the reporting periods based on the invoice date, is as follows:

	As at June 30, 2025 ***RMB'000*** **(unaudited)**	As at December 31, 2024 *RMB'000* (audited)
Within 1 year	**28,853**	23,328
1 to 2 years	**30**	22
Over 2 years	**109**	119
Total	**28,992**	23,469

Trade payables are non-interest-bearing and are normally settled within one month.

12. SHARE CAPITAL

A summary of movements in the Company's share capital is as follows:

	Number of ordinary shares	**Share capital** *RMB'000*
As at December 31, 2023, January 1, 2024 and December 31, 2024 (audited)	125,000,000	125,000
Shares issued upon IPO (unaudited) (note)	16,800,000	16,800
As at June 30, 2025 (unaudited)	141,800,000	141,800

Note:

On June 30, 2025, the Company issued a total of 16,800,000 ordinary shares of RMB1.00 each at the price of HK$30.60 per share by means of global offering.

CORPORATE GOVERNANCE AND OTHER INFORMATION

Compliance with the Corporate Governance Code

The Company was incorporated on June 11, 2020 as a limited liability company under the laws of the PRC, and the H shares of the Company were listed on the Main Board of the Stock Exchange on June 30, 2025 (the "**Listing Date**"), since which time the Corporate Governance Code (the "**Corporate Governance Code**") as set out in Appendix C1 to the Listing Rules has been applicable to the Company.

The Company and our Directors are committed to upholding and implementing the highest standards of corporate governance and recognize the importance of protecting the rights and interests of all Shareholders, including the rights and interests of our minority Shareholders. Save as disclosed below, the Company has complied with all the applicable code provisions set out in the Corporate Governance Code throughout the period from the Listing Date up to the date of this announcement.

Pursuant to code provision C.2.1 in Part 2 of the Corporate Governance Code, companies listed on the Stock Exchange are expected to comply with, but may choose to deviate from the requirement that the responsibilities between the chairperson and the chief executive officer should be segregated and should not be performed by the same individual. We do not have a separate chairperson and chief executive officer and Dr. Xu Qi (徐琪) ("**Dr. Xu**"), our chairperson of the Board, executive Director and chief executive officer, currently performs these two roles. The Board believes that vesting the roles of both chairperson and chief executive officer in the same person has the benefit of ensuring consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired, given that: (1) decision to be made by our Board requires approval by at least a majority of our Directors; (2) Dr. Xu and the other Directors are aware of and undertake to fulfill their fiduciary duties as Directors, which require, among other things, that she acts for the benefit and in the best interests of our Company and will make decisions for our Company accordingly; (3) the balance of power and authority is ensured by the operations of the Board, including three independent non-executive Directors, and has a fairly strong independence element; and (4) the overall strategic and other key business, financial, and operational policies of our Company are made collectively after thorough discussion at both Board, and senior management levels.

The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the Corporate Governance Code, and maintain a high standard of corporate governance practices of the Company.

Model Code for Securities Transactions by Directors and Supervisors of Listed Issuers

The Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules has been applicable to the Company since the Listing Date.

The Company has adopted the Model Code as the code of conduct regarding the Directors' and Supervisors' dealings in the securities of the Company. Having made specific enquiry of all the Directors and Supervisors of the Company, all the Directors and Supervisors confirmed that they have strictly complied with the required standards set out in the Model Code throughout the period from the Listing Date up to the date of this announcement.

Purchase, Sale or Redemption of Listed Securities of the Company

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares (as defined under the Listing Rules)) from the Listing Date up to the date of this announcement. As at June 30, 2025, the Company did not hold any treasury shares (as defined under the Listing Rules).

Audit Committee

The Company has established the Audit Committee in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code. With terms of reference in compliance with the Listing Rules, the Audit Committee comprises three members, namely Mr. Xia Xinsheng (夏心晟), Dr. Yu Cheung Hoi (于常海) and Dr. Zhu Xun (朱迅). Mr. Xia Xinsheng (夏心晟), who holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules, serves as the Chairperson of the Audit Committee.

The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal controls system of the Group, review and approve connected transactions and provide advice and comments to the Board. The Audit Committee has reviewed the unaudited condensed consolidated financial statements of the Group for the six months ended June 30, 2025 and discussed matters with respect to the accounting policies and practices adopted by the Company and internal control with senior management members and Ernst & Young, the auditor of the Company (the "**Auditor**").

The Auditor has reviewed this announcement and the unaudited condensed consolidated financial statements of the Group for the six months ended June 30, 2025 in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

Significant Events after the Reporting Period

There were no significant events that might affect the Company since June 30, 2025 and up to date of this announcement.

Interim Dividend

The Board did not recommend the distribution of an interim dividend for the six months ended June 30, 2025.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at https://medtideinc.com/.

The interim report of the Group for the six months ended June 30, 2025 will be published on the aforesaid websites of the Stock Exchange and the Company and will be dispatched to the Shareholders in due course, if requested.

APPRECIATION

The Board would like to express its sincere gratitude to the shareholders, management team, employees, business partners and customers of the Group for their support and contribution to the Group.

By order of the Board
Medtide Inc.
Dr. Xu Qi
Chairwoman and chief executive officer

Hong Kong, August 29, 2025

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).